



"IMPORTANT"

Whist care is taken prior to acceptance of advertising copy, it is not possible to verify its contents. The Indian Express (P) Limited cannot be held responsible for such contents, nor for any loss or damage incurred as a result of transactions with companies, associations or individuals advertising in its newspapers or Publications. We therefore recommend that readers make necessary inquiries before sending any monies or entering into any agreements with advertisers or otherwise acting on an advertisement in any manner whatsoever.

TRAVANCORE TITANIUM PRODUCTS LIMITED
 Thiruvananthapuram-695021
 E-mail: purchasetp@gmail.com, contract@tplttd.in
E-TENDER NOTICE
 E-tenders are invited from Experienced Contractors / Firms in TWO BID system for the following work in T.T.P.L. Tenders can be submitted only by online through the portal www.etenders.kerala.gov.in
Name of Work: Supply, Installation, Replacement & Commissioning 126 Nos. of RO Membranes in Neutralisation Plant
Tender ID : 2023_TTPL_574479_1
Pre-Bid Meeting : 15.05.2023 at 11 am
Due Date : 24.05.2023
 For more details & tenders please visit our web site www.travancoretitanium.com
 (Sd/-) Head of Department (Commercial)

THIS IS A PUBLIC ANNOUNCEMENT FOR INFORMATION PURPOSES ONLY AND IS NOT A PROSPECTUS ANNOUNCEMENT. THIS DOES NOT CONSTITUTE AN INVITATION OR OFFER TO ACQUIRE, PURCHASE OR SUBSCRIBE TO SECURITIES. THIS PUBLIC ANNOUNCEMENT IS NOT INTENDED FOR PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY OUTSIDE INDIA.



REMUS PHARMACEUTICALS LIMITED
 Corporate Identification Number: U24232GJ2015PLC084536

Our Company was originally incorporated as 'Remus Pharmaceuticals Private Limited' as a private limited company, under the provisions of the Companies Act, 2013 vide Certificate of Incorporation dated September 21, 2015, issued by the Assistant Registrar of Companies, Gujarat. Subsequently, pursuant to a special resolution passed by our Shareholders in the Extra-Ordinary General Meeting held on January 02, 2023, our Company was converted from a private limited company to public limited company and consequently, the name of our Company was changed to "Remus Pharmaceuticals Limited" and a fresh certificate of incorporation dated January 06, 2023 was issued to our Company by the Registrar of Companies, Ahmedabad. The Corporate Identification Number of our Company is U24232GJ2015PLC084536.

Registered Office: 1101 to 1103, South Tower, One 42, B/H Ashok Vatika, Nr. Jayantilal Park BRTS, Ambli bopal Road, Ahmedabad - 380054, Gujarat, India
Website: www.remuspharma.com; **E-Mail:** cs@remuspharma.com; **Telephone No.:** +079- 2999 9857;
Company Secretary and Compliance Officer: Ms. Deval Bakulkumar Patel
PROMOTERS OF OUR COMPANY: MR. ARPIT DEEPAKKUMAR SHAH, MS. ROMA VINODBHAI SHAH, MR. SWAPNIL JATINBHAI SHAH AND MRS. ANAR SWAPNIL SHAH

THE ISSUE

INITIAL PUBLIC ISSUE OF 388000 EQUITY SHARES OF FACE VALUE OF ₹ 10/- EACH OF REMUS PHARMACEUTICALS LIMITED ("RPL" OR THE "COMPANY" OR THE "ISSUER") FOR CASH AT A PRICE OF ₹ 10/- PER EQUITY SHARE INCLUDING A SHARE PREMIUM OF ₹ 10/- PER EQUITY SHARE (THE "ISSUE PRICE") AGGREGATING TO ₹ 3.88 LAKHS (THE "ISSUE"), OF WHICH 19500 EQUITY SHARES OF FACE VALUE OF ₹ 10/- EACH FOR CASH AT A PRICE OF ₹ 10/- PER EQUITY SHARE INCLUDING A SHARE PREMIUM OF ₹ 10/- PER EQUITY SHARE AGGREGATING TO ₹ 1.95 LAKHS WILL BE RESERVED FOR SUBSCRIPTION BY MARKET MAKER TO THE ISSUE (THE "MARKET MAKER RESERVATION PORTION"), THE ISSUE LESS THE MARKET MAKER RESERVATION PORTION I.E. NET ISSUE OF 368500 EQUITY SHARES OF FACE VALUE OF ₹ 10/- EACH AT A PRICE OF ₹ 10/- PER EQUITY SHARE INCLUDING A SHARE PREMIUM OF ₹ 10/- PER EQUITY SHARE AGGREGATING TO ₹ 3.685 LAKHS IS HEREBY REFERRED TO AS THE "NET ISSUE". THE ISSUE AND THE NET ISSUE WILL CONSTITUTE 26.34% AND 25.02%, RESPECTIVELY, OF THE POST ISSUE PAID UP EQUITY SHARE CAPITAL OF OUR COMPANY. THE FACE VALUE OF THE EQUITY SHARES IS ₹ 10/- EACH.

- **QIB Portion : Not more than 50% of the Net Issue**
- **Retail Individual Bidders Portion : Not less than 35% of the Net Issue**
- **Non-Institutional Bidders Portion : Not Less than 15% of the Net Issue**

Price Band: ₹ 1150/- to ₹ 1229/- per Equity Share of Face Value ₹ 10/- each.
The Floor Price is 115.00 times of the Face Value and the Cap Price is 122.90 times of the Face Value.
Bids can be made for a minimum of 100 Equity Shares and in multiples of 100 Equity Shares thereafter.

Risks to Investors:

- The Company is dependent on few numbers of customers for sales. Loss of any of this large customer may affect our revenues and profitability.
- The Merchant Banker associated with the Issue has handled 12 public issues out of which 2 issue closed below issue price on listing date.
- Average cost of acquisition per Equity Share by our Promoters, Mr. Arpit Deepakkumar Shah is ₹ 0.10, Mrs. Roma Vinodhbhai Shah is ₹ 0.10, Mr. Swapnil Jatinbhai Shah is ₹ 0.06, and Mrs. Anar Swapnil Shah is ₹ 9.45 per Equity Share
- The Issue Price at the upper end of the Price Band is ₹ 1229/- per Equity Share.
- Weighted Average Return on Net worth for period Fiscals 2022, 2021 and 2020 is 44.24% and Average Return on Net worth for the Period ended on December 31, 2022 is 37.61%.

Bids can be made for a minimum of 100 Equity Shares and in multiples of 100 Equity Shares thereafter.

ASBA* Simple, Safe, Smart way of Application-Make use of it!!! *Applications Supported by Blocked Amount (ASBA) is a better way of applying to issues by simply blocking the fund in the bank account, investors can avail the same. For details, check section on ASBA below. Mandatory in Public Issues from January 01, 2016. No cheque will be accepted

UPI **UPI-Now available in ASBA for Retail Individual Investors (RII)**** Investors are required to ensure that the bank account used for bidding is linked to their PAN. UPI - Now available in ASBA for RIIs applying through Registered Brokers, DPs & RTAs. RIIs also have the option to submit the application directly to the ASBA Bank (SCSBs) or to use the facility of linked online trading, demat and bank account.

Investors have to apply through the ASBA process. *ASBA will be availed by all the investors except anchor investor. UPI may be availed by Retail Individual Investors. For details on the ASBA and the UPI process, please refer to the details given in ASBA form and abridged prospectus and also please refer to the section "Issue Procedure" beginning on page 246 of the RHP. The process is also available on the website of Association of Investment Bankers of India ("AIBI"), the Stock Exchanges and in the General Information Document.

*ASBA forms can be downloaded from the website National Stock Exchange of India ("NSE") and can be obtained from the list of banks that is displayed on the website of SEBI at www.sebi.gov.in.

**List of banks supporting UPI is also available on the website of SEBI at www.sebi.gov.in. ICICI Bank Limited has been appointed as Sponsor Bank for the Issue, in accordance with the requirements of the SEBI circular dated November 1, 2018, as amended. For UPI related queries, investors can contact NPCI at the toll free number-18001201740 and Mail Id- ipo.upi@npci.org.in. For the list of UPI Apps and Banks live on IPO, please refer to the link www.sebi.gov.in. For issue related grievance investors may contact: Beeline Capital Advisors Private Limited - Mr. Nikhil Shah (079 - 4918 5784) (mb@beelinemb.com).

BID / ISSUE PROGRAM **BID/ISSUE OPENS ON⁽¹⁾ : WEDNESDAY, MAY 17, 2023**
BID/ISSUE CLOSES ON: FRIDAY, MAY 19, 2023

(1) Our company in consultation with the BRLM may consider participation by Anchor Investors. Anchor Investor Bidding date shall be one working day prior to the Bid/Issue opening date, in accordance with SEBI ICDR Regulations.

In case of any revisions in the Price Band, the Bid/Issue Period will be extended by at least three additional Working Days after such revision of the Price Band, subject to the Bid/Issue Period not exceeding 10 Working Days. In cases of force majeure, banking strikes or similar circumstances, our Company may, for reasons to be recorded in writing, extend the Bid/Issue Period for a minimum of three Working Days, subject to the Bid/Issue Period not exceeding 10 Working Days. Any revision in the Price Band and the revised Bid/Issue Period, if applicable, will be widely disseminated by notification to the Stock Exchange, by issuing a press release, and also by indicating the change on the website of the Book Running Lead Managers and the terminals of the other members of the Syndicate and by intimation to SCSBs, the Sponsor Bank, Registered Brokers, Collecting Depository Participants and Registrar and Share Transfer Agents.

This Issue is being made through the Book Building Process, in terms of Rule 19(2)(b) of the Securities Contracts (Regulation) Rules, 1957, as amended ("SCRR") read with Regulation 229 of the SEBI ICDR Regulations and in compliance with Regulation 253 of the SEBI ICDR Regulations, wherein not more than 50.00% of the Net Issue shall be available for allocation on a proportionate basis to Qualified Institutional Buyers ("QIBs") (the "QIB Portion"), provided that our Company may, in consultation with the Book Running Lead Manager, allocate up to 60% of the QIB Portion to Anchor Investors on a discretionary basis in accordance with the SEBI ICDR Regulations ("Anchor Investor Portion"), of which one-third shall be reserved for domestic Mutual Funds, subject to valid Bids being received from domestic Mutual Funds at or above the Anchor Investor Allocation Price. In the event of under-subscription, or non-allocation in the Anchor Investor Portion, the balance Equity Shares shall be added to the Net QIB Portion. Further, 5.00% of the Net QIB Portion shall be available for allocation on a proportionate basis to Mutual Funds only, and the remainder of the Net QIB Portion shall be available for allocation on a proportionate basis to all QIB Bidders, including Mutual Funds, subject to valid Bids being received at or above the Issue Price. However, if the aggregate demand from Mutual Funds is less than 5.00% of the Net QIB Portion, the balance Equity Shares available for allocation in the Mutual Fund Portion will be added to the remaining Net QIB Portion for proportionate allocation to QIBs. Further, not less than 15.00% of the Net Issue shall be available for allocation on a proportionate basis to Non-Institutional Investors and not less than 35.00% of the Net Issue shall be available for allocation to Retail Individual Investors in accordance with the SEBI ICDR Regulations, subject to valid Bids being received from them at or above the Issue Price. All Bidders (except Anchor Investors) are required to participate in the Issue by mandatorily utilizing the Application Supported by Blocked Amount ("ASBA") process by providing details of their respective ASBA Account (as defined hereinafter) in which the corresponding Bid Amounts will be blocked by the Self Certified Syndicate Banks ("SCSBs") or under the UPI Mechanism, as the case may be, to the extent of respective Bid Amounts. For details, see "Issue Procedure" on page 246 of Red Herring Prospectus.

Bidders / Applicants should note that on the basis of PAN, DP ID and Client ID as provided in the Bid Cum Application Form, the Bidders / Applicants may be deemed to have authorized the Depositories to provide the Registrar to the Issue, any requested Demographic Details of the Bidders / Applicants as available on the records of the depositories. These Demographic Details may be used, among other things, for or unblocking of ASBA Account or for other correspondence(s) related to an Issue. Bidders / Applicants are advised to update any changes to their Demographic Details as available in the records of the Depository Participant to ensure accuracy of records. Any delay resulting from failure to update the Demographic Details would be at the Applicants' sole risk. Bidders / Applicants should ensure that PAN, DP ID and the Client ID are correctly filled in the Bid Cum Application Form. The PAN, DP ID and Client ID provided in the Bid Cum Application Form should match with the PAN, DP ID and Client ID available in the Depository database, otherwise, the Bid Cum Application Form is liable to be rejected. Bidders / Applicants should ensure that the beneficiary account provided in the Bid Cum Application Form is active.

Contents of the Memorandum of Association of the Company as regards its objects: For information on the main objects and other objects of our Company, see "History and Certain Corporate Matters" on page 156 of the Red Herring Prospectus and Clause III of the Memorandum of Association of our Company. The Memorandum of Association of our Company is a material document for inspection in relation to the Issue. For further details, see the section "Material Contracts and Documents for Inspection" on page 313 of the Red Herring Prospectus.

Liability of Members of the Company: Limited by shares.

AMOUNT OF SHARE CAPITAL OF THE COMPANY AND CAPITAL STRUCTURE: The Authorised share capital of the Company is ₹ 2,00,00,000 divided into 20,00,000 Equity Shares of ₹ 10 each. The issued, subscribed and paid-up share capital of the Company before the Issue is ₹ 1,08,50,000 divided into 10,85,000 Equity Shares of ₹ 10 each. For details of the Capital Structure, see "Capital Structure" on the page 57 of the Red Herring Prospectus.

NAMES OF THE SIGNATORIES TO THE MEMORANDUM OF ASSOCIATION OF THE COMPANY AND THE NUMBER OF EQUITY SHARES SUBSCRIBED BY THEM: Given below are the names of the signatories of the Memorandum of Association of the Company and the number of Equity Shares subscribed for by them at the time of signing of the Memorandum of Association of our Company. Mr. Arpit Deepakkumar Shah-2500 Equity Shares, Mrs. Roma Vinodhbhai Shah - 2500 Equity Shares, Mr. Jatin Siddharth Shah-1000 Equity Shares, Mr. Swapnil Jatinbhai Shah-1000 Equity Shares and M/s. Espee Lifesciences Private Limited-3000 Equity Shares aggregating to 10,000 Equity Shares of ₹ 10/- each. For details of the Capital Structure, see "Capital Structure" on the page 57 of the Red Herring Prospectus.

LISTING: The Equity Shares issued through the Red Herring Prospectus are proposed to be listed on the Emerge Platform of National Stock Exchange of India Limited. Our Company has received an in-principle approval from the National Stock Exchange of India Limited for the listing of the Equity Shares pursuant to letter dated April 28, 2023. For the purposes of the Issue, the Designated Stock Exchange shall be Emerge Platform of National Stock Exchange of India Limited. A signed copy of the Red Herring Prospectus has been submitted with the ROC on May 06, 2023 and Prospectus shall be submitted for registration to the RoC in accordance with Section 26(4) of the Companies Act, 2013. For details of the material contracts and documents available for inspection from the date of the Red Herring Prospectus up to the Bid/ Issue Closing Date, see "Material Contracts and Documents for Inspection" on page 313 of the Red Herring Prospectus.

DISCLAIMER CLAUSE OF SECURITIES AND EXCHANGE BOARD OF INDIA (SEBI): Since the Issue is being made in terms of Chapter IX of the SEBI (ICDR) Regulations, 2018, the Draft Red Herring Prospectus/Red Herring Prospectus was not filed with SEBI. In terms of the SEBI Regulations, the SEBI shall not issue any observation on the Offer Document. Hence there is no such specific disclaimer clause of SEBI. However, investors may refer to the entire disclaimer Clause of SEBI beginning on page 225 of the RHP.

DISCLAIMER CLAUSE OF NSE (THE DESIGNATED STOCK EXCHANGE): It is to be distinctly understood that the permission given by National Stock Exchange of India Limited ("NSE") should not in any way be deemed or construed that the offer document has been cleared or approved by NSE nor does it certify the correctness or completeness of any of the contents of the Offer Document. The investors are advised to refer to page 226 of the Red Herring Prospectus for the full text of the Disclaimer clause of National Stock Exchange of India Limited.

GENERAL RISK: Investments in equity and equity-related securities involve a degree of risk and investors should not invest any funds in this Issue unless they can afford to take the risk of losing their investment. Investors are advised to read the risk factors carefully before taking an investment decision in this Issue. For taking an investment decision, investors must rely on their own examination of the Issuer and this Issue, including the risks involved. The Equity Shares have not been recommended or approved by the Securities and Exchange Board of India ("SEBI"), nor does SEBI guarantee the accuracy or adequacy of the contents of this Red Herring Prospectus. Specific attention of the investors is invited to "Risk Factors" on page 26 of the Red Herring Prospectus.

BOOK RUNNING LEAD MANAGER TO THE ISSUE	REGISTRAR TO THE ISSUE	COMPANY SECRETARY AND COMPLIANCE OFFICER
 BEELINE CAPITAL ADVISORS PRIVATE LIMITED SEBI Registration Number: INM000012917 Address: B 1311-1314, Thirteenth Floor, Ship Corporation Park, Rajpath Rangoli Road, Thaltej, Ahmedabad, Gujarat - 380054, India. Tel. Number: 079 4918 5784 Email: mb@beelinemb.com Investors Grievance Id: ig@beelinemb.com Website: www.beelinemb.com Contact Person: Mr. Nikhil Shah CIN: U67190GJ2020PTC114322	 LINK INTIME INDIA PRIVATE LIMITED SEBI Registration Number: INR000004058 Address: C-101, 1st Floor, 247 Park, Lal Bahadur Shastri Marg, Vikhroli (West), Mumbai, Maharashtra, India - 400 083. Tel. Number: +91 810 811 4949 Fax: +91 22 4918 6195 Email Id: remuspharmaceuticals.ipa@linkintime.co.in Investors Grievance Id: remuspharmaceuticals.ipa@linkintime.co.in Website: www.linkintime.co.in Contact Person: Shantli Goapalkrishnan CIN: U67190MH1999PTC118368	 REMUS PHARMACEUTICALS LIMITED Ms. Deval Bakulkumar Patel Address: 1101 to 1103, South Tower, One 42, B/H Ashok Vatika, Nr. Jayantilal Park BRTS, Ambli Bopal Road, Ahmedabad - 380054, Gujarat, India Tel No. : +079- 2999 9857; Email: cs@remuspharma.com Website: www.remuspharma.com Investors can contact the Company Secretary and Compliance Officer or the BRLMs or the Registrar to the Issue in case of any pre-issue or post-issue related problems, such as non-receipt of letters of Allotment, non-credit of Allotted Equity Shares in the respective beneficiary account and refund orders, etc.
<p>AVAILABILITY OF RED HERRING PROSPECTUS: Investors are advised to refer to the Red Herring Prospectus and the Risk Factors contained therein before applying in the Issue. Full copy of the Red Herring Prospectus is available on the website of the SEBI at www.sebi.gov.in, website of the Company at www.remuspharma.com, the website of the BRLM to the Issue at www.beelinemb.com, the website of NSE i.e. www.nseindia.com, respectively.</p> <p>AVAILABILITY OF BID-CUM-APPLICATION FORMS: Bid-Cum-Application forms can be obtained from the Registered Office of the Company: Remus Pharmaceuticals Limited, Telephone: +079- 2999 9857; BRLM: Beeline Capital Advisors Private Limited, Telephone: 079 4918 5784 and the Syndicate Member: Sunflower Broking Private Limited Telephone: +91 8905344010 and at the selected locations of the Sub-Syndicate Members, Registered Brokers, RTAs and CDPs participating in the Issue. Bid-cum-application Forms will also be available on the websites of NSE and the designated branches of SCSBs, the list of which is available at websites of the stock exchanges and SEBI.</p> <p>ESCROW COLLECTION BANK/ REFUND BANK/ PUBLIC ISSUE ACCOUNT BANK/ SPONSOR BANK: ICICI Bank Limited. UPI: Retail Individual Bidders can also Bid through UPI Mechanism. All capitalized terms used herein and not specifically defined shall have the same meaning as ascribed to them in the Red Herring Prospectus.</p>		

On behalf of Board of Directors For, REMUS PHARMACEUTICALS LIMITED
 Sd/-
 Mr. Swapnil Jatinbhai Shah
 Chairman and Whole Time Director

Place: Ahmedabad
Date: May 09, 2023
 Disclaimer: Remus Pharmaceuticals Limited is proposing, subject to applicable statutory and regulatory requirements, receipt of requisite approvals, market conditions and other considerations, to make an initial public offer of its Equity Shares and has filed the RHP with the Registrar of Companies, Ahmedabad on May 06, 2023 and thereafter with SEBI and the Stock Exchanges. The RHP is available on the websites of SEBI at www.sebi.gov.in, website of the Company at www.remuspharma.com, the website of the BRLM to the Issue at www.beelinemb.com, the website of NSE i.e. www.nseindia.com, respectively. Any potential investors should note that investment in equity shares involves a high degree of risk and for details relating to the same, please refer to the RHP including the section titled "Risk Factors" beginning on page 26 of Red Herring Prospectus.
 The Equity Shares have not been and will not be registered under the U.S. Securities Act of 1933, as amended (the "Securities Act") or any state securities laws in the United States, and unless so registered, and may not be issued or sold in the United States, except pursuant to an exemption from, or in a transaction not subject to, the registration requirements of the Securities Act and in accordance with any applicable U.S. state securities laws. The Equity Shares are being issued and sold outside the United States in "offshore transactions" in reliance on Regulation S under the Securities Act and the applicable laws of each jurisdiction where such issues and sales are made. There will be no public offering in the United States.

OFFER OPENING ADVERTISEMENT FOR THE BUYBACK OF EQUITY SHARES THROUGH TENDER OFFER UNDER THE SECURITIES AND EXCHANGE BOARD OF INDIA (BUYBACK OF SECURITIES) REGULATIONS, 2018, AS AMENDED, ("SEBI BUYBACK REGULATIONS") FOR THE ATTENTION OF EQUITY SHAREHOLDERS/ BENEFICIAL OWNERS OF THE EQUITY SHARES OF TEAMLEASE SERVICES LIMITED.



TEAMLEASE SERVICES LIMITED

CIN: L74140KA2000PLC118995

Registered Office: 315 Work Avenue Campus, Ascent Building, Koramangala Industrial Layout, Jyoti Nivas College Road, Koramangala , Bangalore - 560 095. Tel. No.: +91-80-6824 3000 | Fax. No.: +91-80-6824 3001
Company Secretary and Compliance Officer: Alaka Chanda,
E-mail: corporateaffairs@teamlease.com; **Website:** group.teamlease.com

PUBLIC ANNOUNCEMENT FOR THE BUYBACK OF EQUITY SHARES OF TEAMLEASE SERVICES LIMITED IN CONNECTION WITH THE BUYBACK OF EQUITY SHARES THROUGH THE TENDER OFFER UNDER THE SEBI BUYBACK REGULATIONS OFFER FOR BUYBACK UPTO 3,27,869 (THREE LAKH TWENTY SEVEN THOUSAND EIGHT HUNDRED AND SIXTY NINE ONLY) FULLY PAID UP EQUITY SHARES OF FACE VALUE OF 10 (INDIAN RUPEES TEN ONLY) EACH, REPRESENTING 1.92% OF THE EQUITY SHARES IN THE EXISTING TOTAL PAID-UP EQUITY CAPITAL OF THE COMPANY FROM ALL ELIGIBLE SHAREHOLDERS (EQUITY SHAREHOLDERS AS ON THE RECORD DATE, BEHIND APRIL 03, 2023) ON A PROPORTIONATE BASIS, THROUGH THE 'TENDER OFFER' PROCESS, AT A PRICE OF 3,050/- (RUPEES THREE THOUSAND FIFTY ONLY) PER EQUITY SHARE, PAYABLE IN CASH, FOR AN AGGREGATE MAXIMUM AMOUNT NOT 1,00,00,00,450 (INDIAN RUPEES ONE HUNDRED CRORE AND FOUR FIFTY RUPEES ONLY) (THE "BUYBACK") EXCLUDING THE TRANSACTION COSTS.

This Offer Opening Advertisement is to be read together with (a) the public announcement dated March 17, 2023, published on March 20, 2023, in all editions of the English national daily newspaper, namely Financial Express, in all editions of the Hindi national daily newspaper, Jansatta and in Bangalore edition of Kannada daily newspaper, namely, HosaDigantha (Kannada being the regional language of Bangalore, Karnataka wherein the registered office of the Company is located), each with wide circulation and (b) the letter of offer dated May 01, 2023 in connection with the Buyback ("Letter of Offer").

In terms of Regulation 8(i) of the SEBI Buyback Regulations, the Draft Letter of Offer was submitted to SEBI on March 28, 2023. SEBI, vide its letter bearing reference No. SEBI/HO/CFD/CFD-DCR1/P/OW/2023/17025/1 dated April 26, 2023 ("SEBI Final Observation Letter"), issued its comments on the Draft Letter of Offer in terms of Regulation 8(ii) of the SEBI Buyback Regulations. These comments have been suitably incorporated in the Letter of Offer.

The dispatch of the Letter of Offer to the Eligible Shareholders of the Company holding Equity Shares on the Record Date i.e. April 03, 2023 has been completed by May 04, 2023 through electronic mode to the shareholders whose e-mail ids are available with the Company and through Speed post/registered post at the address registered in India for all the remaining shareholders.

The Letter of Offer and the Tender Forms are available on the website of the Registrar of the Company, i.e. KFin Technologies Limited i.e. www.kfintech.com, Company, i.e. group.teamlease.com, Manager to the Buyback, i.e. Edelweiss Financial Services Limited i.e. www.edelweissfin.com, BSE Limited, i.e. www.bseindia.com and National Stock Exchange of India Limited i.e. www.nseindia.com. In case of non-receipt of the Letter of Offer, the Eligible Shareholders, if they so desire, may download the Letter of Offer or the Tender Forms from the websites indicated above.

The schedule of activities for the Buyback is as follows:

Sr. No.	Activity	Schedule of Activities	
		Day	Date
1.	Date of Board Meeting approving the proposal for the Buyback	Friday	February 03, 2023
2.	Date of declaration of results of the postal ballot for special resolution by the Equity Shareholders, approving the Buyback	Thursday	March 16, 2023
3.	Date of Public Announcement for the Buyback	Friday	March 17, 2023
4.	Date of publication of the Public Announcement for the Buyback in newspapers	Monday	March 20, 2023
5.	Record Date for determining the names of the Eligible Shareholders and the Buyback Entitlement	Monday	April 03, 2023
6.	Buyback Opening Date	Friday	May 12, 2023
7.	Buyback Closing Date	Thursday	May 25, 2023
8.	Last date of receipt of completed Tender Forms and other specified documents including physical certificates (if and as applicable) by the Registrar to the Buyback	Thursday	May 25, 2023
9.	Last date of verification of Tender Forms by Registrar to the Buyback	Wednesday	May 31, 2023
10.	Last date of intimation to the Designated Stock Exchange regarding Acceptance/non-acceptance of Equity Shares by the Registrar to the Buyback	Friday	June 02, 2023
11.	Last date of completion of settlement of bids by the Clearing Corporation/ Stock Exchanges	Monday	June 05, 2023
12.	Last date of dispatch of share certificate(s) by the Registrar to the Buyback/payment to Eligible Shareholders/ unblocking/ return of unaccepted Demat Shares by the Stock Exchanges to Eligible Shareholders/Seller Broker	Monday	June 05, 2023
13.	Last date of payment of consideration to Eligible Shareholders who participated in the Buyback	Monday	June 05, 2023
14.	Last date of extinguishment of the Equity Shares bought back	Monday	June 12, 2023

Note: Where last dates are mentioned for certain activities, such activities may take place on or before the respective last dates. We request you to refer to the website of the Designated Stock Exchange for notice, if any, in this regard.

It may please be noted that the Buyback shall be implemented using the "Mechanism for acquisition of shares through Stock Exchange" notified by the SEBI Circulars and following the procedure prescribed in the Companies Act, 2013 read with the Companies (Share Capital and Debentures) Rules, 2014 and the SEBI Buyback Regulations and as may be determined by the Board and on such terms and conditions as may be permitted by law from time to time. In this regard, the Company shall request BSE being the designated stock exchange ("Designated Stock Exchange") to provide a separate window (the "Acquisition Window") to facilitate placing of sell orders by the Eligible Shareholders who wish to tender their Equity Shares in the Buyback. The details of the Acquisition Window will be as specified by BSE from time to time. During the Tendering Period all Eligible Shareholders may place orders in the Acquisition Window, through their respective stock brokers ("Seller Broker") during normal trading hours of the secondary market.

In the event the Seller Broker of any Eligible Shareholder is not registered with BSE as a trading member/ stockbroker/, then that Eligible Shareholder can approach any BSE registered stock broker and can register himself by using web based unique client code application ("UCI online") facility through that BSE registered stock broker (after submitting all details as may be required by such BSE registered stock broker in compliance with applicable law). In case the Eligible Shareholders are unable to register himself by using UCI online facility through any other BSE registered stock broker, then that Eligible Shareholder may approach the Company's Broker i.e., Nuvama Wealth Management Limited (formerly known as Edelweiss Securities Limited) to place their bids subject to completion of KYC requirements by the Company's Broker.

For details of the procedure for tender and settlement, please refer to the "Procedure for Tender Offer and Settlement" on page 47 of the Letter of Offer. The non-receipt of the Letter of Offer, by or accidental omission to dispatch the Letter of Offer to, any person who is eligible to receive the Offer, shall not invalidate the Offer to any person who is eligible to receive this Letter of Offer to participate in the Buyback. For the Eligible Shareholders holding Equity Shares in demat form, submission of Tender Form and TRS to the Company, Manager or the Registrar is not mandatory. In case of non-receipt of the Letter of Offer, Eligible Shareholders may participate in the offer by applying on the Tender Form downloaded from the Company's website group.teamlease.com, or Registrar's portal (direct web link of the RTA) at <https://kosmic.kfintech.com/karisma/buybackoffer2.aspx> or obtain a duplicate copy of the same by writing to the Registrar to the Buyback or by providing their application on plain paper in writing signed by such shareholder (in case jointly held then signed by all shareholders), stating name, address, number of shares held, Folio No, Client ID number, DP name, DP ID number, number of Equity Shares tendered and other relevant documents. Eligible Shareholder(s) have to ensure that their bid is entered in the Acquisition Window prior to the closure of the Offer. Please note that the Company shall accept Equity Shares from the Eligible Shareholders on the basis of their holding and Buyback Entitlement. Eligible Shareholder(s) who intend to participate in the Buyback using the 'plain paper' option as mentioned in this paragraph are advised to confirm their Buyback Entitlement from the Registrar to the Buyback, before participating in the Buyback.

MANAGER TO THE BUYBACK	REGISTRAR TO THE BUYBACK
 EDELWEISS FINANCIAL SERVICES LIMITED 801 - 804, Wing A, Building No 3, Inspire BKC, G Block, Bandra Kurla Complex, Bandra East, Mumbai - 400051 Tel. No.: +91 22 4009 4400 Contact Person: Lokesh Shah Email: teamlease@edelweissfin.com Website: www.edelweissfin.com SEBI Registration No.: INM000010650 CIN: L99999MH1995PLC094641	 KFIN TECHNOLOGIES LIMITED Selenium, Tower B, Plot No- 31 and 32, Financial District, Nanakramguda, Serilingampally, Hyderabad, Rangareddi - 500 032 Telangana, India Tel. No.: +91 40 67162222; Fax No.: +91 40 6716 1563 Toll free No.: 18003094001; Contact Person: M Murlikrishna Email: tsl.buyback@kfintech.com Investor Grievance Id: inward.ris@kfintech.com Website: www.kfintech.com SEBI Registration No.: INR000000221 Validity Period: Permanent CIN: L72400TG2017PLC117649

Capitalised terms used but not defined in this Offer Opening Advertisement shall have the meaning assigned to such terms in the Letter of Offer.

FOR AND ON BEHALF OF THE BOARD OF DIRECTORS OF TEAMLEASE SERVICES LIMITED.

Sd/- Name: Ashok Kumar Nedurumalli Designation: Managing Director DIN: 00151814	Sd/- Name: Rituparna Chakraborty Designation: Executive Director DIN: 07332241	Sd/- Name: Alaka Chanda Designation: Company Secretary and Compliance Officer Membership No.: F10911
---	--	--

Date : May 09, 2023
 Place

कम्पा सुचना (अचल संपत्ति हेतु) नियम 8-(1)
अबकि, अहमदाबादस्थित ने आईआईएफएल होम फायनेंस लिमिटेड (पूर्व में इंडिया इन्वोल्वमेंट्स प्राइवेट लिमिटेड) (आईआईएफएल-एफएल) के प्राधिकृत अधिकारी के रूप में शिवाजी परिवारियों के प्रतिनिधित्व एवं प्रभुत्व के अंतर्गत अतिरिक्त 2022 के अंतर्गत और प्रतिभूति हित (प्रवर्तन) नियमवली 2002 के नियम 3 के तहत चर्चित धारा 13(12) के अंतर्गत प्रकृत अधिकारियों के प्रयोगकर्ता, कंपनी के प्राधिकृत अधिकारी द्वारा यह इतना निम्न बताना आवश्यक/सह-आवश्यक है कि, उक्त सुचना की प्रतिलिपि को 60 दिनों के अंदर, सुचना में उल्लिखित सार के प्राधिकृत हेतु, एक नाम सुचना प्रिंट की हो।

indianexpress.com
I arrive at a conclusion not an assumption. Inform your opinion with detailed analysis.
The Indian EXPRESS JOURNALISM OF COURAGE

THIS IS A PUBLIC ANNOUNCEMENT FOR INFORMATION PURPOSES ONLY AND IS NOT A PROSPECTUS ANNOUNCEMENT. THIS DOES NOT CONSTITUTE AN INVITATION OR OFFER TO ACQUIRE, PURCHASE OR SUBSCRIBE TO SECURITIES. THIS PUBLIC ANNOUNCEMENT IS NOT INTENDED FOR PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY OUTSIDE INDIA.



REMUS PHARMACEUTICALS LIMITED
Corporate Identification Number: U24232GJ2015PLC084536

Our Company was originally incorporated as "Remus Pharmaceuticals Private Limited" as a private limited company, under the provisions of the Companies Act, 2013 vide Certificate of Incorporation dated September 21, 2015, issued by the Assistant Registrar of Companies, Gujarat.

Registered Office: 1101 to 1103, South Tower, One 42, B/H Ashok Vatika, Nr. Jayantilal Park BRTS, Ambli bopal Road, Ahmedabad - 380054, Gujarat, India
Website: www.remuspharma.com; E-Mail: cs@remuspharma.com; Telephone No: +079- 2999 9857;
Company Secretary and Compliance Officer: Ms. Deval Bakulkumar Patel

PROMOTERS OF OUR COMPANY: MR. ARPIT DEEPAKKUMAR SHAH, MS. ROMA VINODBHAI SHAH, MR. SWAPNIL JATINBHAI SHAH AND MRS. ANAR SWAPNIL SHAH

THE ISSUE

INITIAL PUBLIC ISSUE OF 388000 EQUITY SHARES OF FACE VALUE OF ₹ 10/- EACH OF REMUS PHARMACEUTICALS LIMITED ("RPL" OR THE "COMPANY" OR THE "ISSUER") FOR CASH AT A PRICE OF ₹ 10/- PER EQUITY SHARE INCLUDING A SHARE PREMIUM OF ₹ 10/- PER EQUITY SHARE (THE "ISSUE PRICE") AGGREGATING TO ₹ 3,88,00,000 (THE "ISSUE"), OF WHICH 19500 EQUITY SHARES OF FACE VALUE OF ₹ 10/- EACH FOR CASH AT A PRICE OF ₹ 10/- PER EQUITY SHARE INCLUDING A SHARE PREMIUM OF ₹ 10/- PER EQUITY SHARE AGGREGATING TO ₹ 1,95,00,000 (THE "CASH") WILL BE RESERVED FOR SUBSCRIPTION BY MARKET MAKER TO THE ISSUE (THE "MARKET MAKER RESERVATION PORTION").

- QIB Portion : Not More than 50% of the Net Issue
Retail Individual Bidders Portion : Not less than 35% of the Net Issue
Non-Institutional Bidders Portion : Not Less than 15% of the Net Issue
Price Band: ₹ 1150/- to ₹ 1229/- per Equity Share of Face Value ₹ 10/- each.
The Floor Price is 115.00 times of the Face Value and the Cap Price is 122.90 times of the Face Value.
Bids can be made for a minimum of 100 Equity Shares and in multiples of 100 Equity Shares thereafter.

Risks to Investors:
(i) The Company is dependent on few numbers of customers for sales. Loss of any of this large customer may affect our revenues and profitability.
(ii) The Merchant Banker associated with the Issue has handled 12 public issues out of which 2 issue closed below issue price on listing date.

Bids can be made for a minimum of 100 Equity Shares and in multiples of 100 Equity Shares thereafter.

ASBA Simple, Safe, Smart way of Application- Make use of it!!!
*Applications Supported by Blocked Amount (ASBA) is a better way of applying to issues by simply blocking the fund in the bank account, investors can avail the same. For details, check section on ASBA below. Mandatory in Public Issues from January 01, 2016. No cheque will be accepted

UPI Now available in ASBA for Retail Individual Investors (RII)**
Investors are required to ensure that the bank account used for bidding is linked to their PAN. UPI - Now available in ASBA for RIIs applying through Registered Brokers, DPs & RTAs. RIIs also have the option to submit the application directly to the ASBA Bank (SCSBs) or to use the facility of linked online trading, demat and bank account.

Investors have to apply through the ASBA process. *ASBA has to be availed by all the investors except anchor investor. UPI may be availed by Retail Individual Investors. For details on the ASBA and the UPI process, please refer to the details given in ASBA form and abridged prospectus and also please refer to the section "Issue Procedure" beginning on page 246 of the RHP. The process is also available on the website of Association of Investment Bankers of India ("AIBI"), the Stock Exchanges and in the General Information Document.

*ASBA forms can be downloaded from the website National Stock Exchange of India ("NSE") and can be obtained from the list of banks that is displayed on the website of SEBI at www.sebi.gov.in.
**List of banks supporting UPI is also available on the website of SEBI at www.sebi.gov.in. ICICI Bank Limited has been appointed as Sponsor Bank for the Issue, in accordance with the requirements of the SEBI circular dated November 1, 2018, as amended. For UPI related queries, investors can contact NPCI at the toll free number- 18001201740 and Mail id- ipo.upi@npci.org.in. For the list of UPI Apps and Banks live on IPO, please refer to the link www.sebi.gov.in. For issue related grievance investors may contact: Beeline Capital Advisors Private Limited - Mr. Nikhil Shah (079 - 4918 5784) (mb@beelineb.com)

BID / ISSUE PROGRAM
BID/ISSUE OPENS ON: WEDNESDAY, MAY 17, 2023
BID/ISSUE CLOSES ON: FRIDAY, MAY 19, 2023

(1) Our company in consultation with the BRLM may consider participation by Anchor Investors. Anchor Investor Bidding date shall be one working day prior to the Bid/Issue opening date, in accordance with SEBI ICDR Regulations.

In case of any revisions in the Price Band, the Bid/Issue Period will be extended by at least three additional Working Days after such revision of the Price Band, subject to the Bid/Issue Period not exceeding 10 Working Days. In cases of force majeure, banking strike or similar circumstances, our Company may, for reasons to be recorded in writing, extend the Bid/Issue Period for a minimum of three Working Days, subject to the Bid/Issue Period not exceeding 10 Working Days. Any revision in the Price Band and the revised Bid/Issue Period, if applicable, will be widely disseminated by notification to the Stock Exchange, by issuing a press release, and also by indicating the change on the website of the Book Running Lead Managers and the terminals of the other members of the Syndicate and by intimation to SCSBs, the Sponsor Bank, Registered Brokers, Collecting Depository Participants and Registrar and Share Transfer Agents.

This Issue is being made through the Book Building Process, in terms of Rule 19(2)(b) of the Securities Contracts (Regulation) Rules, 1957, as amended ("SCRR") read with Regulation 229 of the SEBI ICDR Regulations and in compliance with Regulation 253 of the SEBI ICDR Regulations, wherein not more than 50.00% of the Net Issue shall be available for allocation on a proportionate basis to Qualified Institutional Buyers ("QIBs") (the "QIB Portion"), provided that our Company may, in consultation with the Book Running Lead Manager, allocate up to 60% of the QIB Portion to Anchor Investors on a discretionary basis in accordance with the SEBI ICDR Regulations ("Anchor Investor Portion"), of which one-third shall be reserved for domestic Mutual Funds, subject to valid Bids being received from domestic Mutual Funds at or above the Anchor Investor Allocation Price. In the event of under-subscription, or non-allocation in the Anchor Investor Portion, the balance Equity Shares shall be added to the Net QIB Portion. Further, 5.00% of the Net QIB Portion shall be available for allocation on a proportionate basis to Mutual Funds only, and the remainder of the Net QIB Portion shall be available for allocation on a proportionate basis to all QIB Bidders, including Mutual Funds, subject to valid Bids being received at or above the Issue Price. However, if the aggregate demand from Mutual Funds is less than 5.00% of the Net QIB Portion, the balance Equity Shares available for allocation in the Mutual Fund Portion will be added to the remaining Net QIB Portion for proportionate allocation to QIBs. Further, not less than 15.00% of the Net Issue shall be available for allocation on a proportionate basis to Non-Institutional Investors and not less than 35.00% of the Net Issue shall be available for allocation to Retail Individual Investors in accordance with the SEBI ICDR Regulations, subject to valid Bids being received from them at or above the Issue Price. All Bidders (except Anchor Investors) are required to participate in the Issue by mandatorily utilizing the Application Supported by Blocked Amount ("ASBA") process by providing details of their respective ASBA Account (as defined hereinafter) in which the corresponding Bid Amounts will be blocked by the Self Certified Syndicate Banks ("SCSBs") or under the UPI Mechanism, as the case may be, to the extent of respective Bid Amounts. For details, see "Issue Procedure" on page 246 of Red Herring Prospectus.

Bidders / Applicants should note that on the basis of PAN, DP ID and Client ID as provided in the Bid cum Application Form, the Bidders/Applicants may be deemed to have authorized the Depositories to provide to the Registrar to the Issue, any requested Demographic Details of the Bidders/Applicants as available on the records of the Depositories. These Demographic Details may be used, among other things, for or in connection with the ASBA Account or for other correspondence(s) related to an issue. Bidders/Applicants are advised to update any changes to their Demographic Details as available in the records of the Depository Participant to ensure accuracy of records. Any delay resulting from failure to update the Demographic Details would be at the Applicants' sole risk. Bidders / Applicants should ensure that PAN, DP ID and the Client ID are correctly filled in the Bid cum Application Form. The PAN, DP ID and Client ID provided in the Bid cum Application Form should match with the PAN, DP ID and Client ID available in the Depository database, otherwise, the Bid cum Application Form is liable to be rejected. Bidders/Applicants should ensure that the beneficiary account provided in the Bid cum Application Form is active.

Contents of the Memorandum of Association of the Company as regards its objects: For information on the main objects and other objects of our Company, see "History and Certain Corporate Matters" on page 156 of the Red Herring Prospectus and Clause III of the Memorandum of Association of our Company. The Memorandum of Association of our Company is a material document for inspection in relation to the Issue. For further details, see the section "Material Contracts and Documents for Inspection" on page 313 of the Red Herring Prospectus.

Liability of Members of the Company: Limited by shares.
AMOUNT OF SHARE CAPITAL OF THE COMPANY AND CAPITAL STRUCTURE: The Authorised share capital of the Company is ₹ 2,00,00,000 divided into 20,00,000 Equity Shares of ₹ 10 each. The issued, subscribed and paid-up share capital of the Company before the Issue is ₹ 1,08,50,000 divided into 10,85,000 Equity Shares of ₹ 10 each. For details of the Capital Structure, see "Capital Structure" on the page 57 of the Red Herring Prospectus.

NAMES OF THE SIGNATORIES TO THE MEMORANDUM OF ASSOCIATION OF THE COMPANY AND THE NUMBER OF EQUITY SHARES SUBSCRIBED BY THEM: Given below are the names of the signatories of the Memorandum of Association of the Company and the number of Equity Shares subscribed for by them at the time of signing of the Memorandum of Association of our Company: Mr. Arpit Deepakkumar Shah- 2500 Equity Shares, Mrs. Roma Vinodhbhai Shah - 2500 Equity Shares, Mr. Jatin Siddharth Shah- 1000 Equity Shares, Mr. Swapnil Jatindbhai Shah- 1000 Equity Shares and M/s. Espee Lifesciences Private Limited-3000 Equity Shares aggregating to 10,000 Equity Shares of ₹ 10/- each. For details of the Capital Structure, see "Capital Structure" on the page 57 of the Red Herring Prospectus.

LISTING: The Equity Shares issued through the Red Herring Prospectus are proposed to be listed on the Emerge Platform of National Stock Exchange of India Limited. Our Company has received an in-principle approval from the National Stock Exchange of India Limited for the listing of the Equity Shares pursuant to letter dated April 28, 2023. For the purposes of the Issue, the Designated Stock Exchange shall be Emerge Platform of National Stock Exchange of India Limited. A signed copy of the Red Herring Prospectus has been submitted with the ROC or May 06, 2023 and Prospectus shall be submitted for registration to the RoC in accordance with Section 26(4) of the Companies Act, 2013. For details of the material contracts and documents available for inspection from the date of the Red Herring Prospectus up to the Bid/ Issue Closing Date, see "Material Contracts and Documents for Inspection" on page 313 of the Red Herring Prospectus.

DISCLAIMER CLAUSE OF SECURITIES AND EXCHANGE BOARD OF INDIA (SEBI): Since the Issue is being made in terms of Chapter IX of the SEBI (ICDR) Regulations, 2018, the Draft Red Herring Prospectus/Red Herring Prospectus was not filed with SEBI. In terms of the SEBI Regulations, the SEBI shall not issue any observation on the Offer Document. Hence there is no such specific disclaimer clause of SEBI. However, investors may refer to the entire Disclaimer Clause of SEBI beginning on page 225 of the RHP.

DISCLAIMER CLAUSE OF NSE (THE DESIGNATED STOCK EXCHANGE): It is to be distinctly understood that the permission given by National Stock Exchange of India Limited ("NSE") should not in any way be deemed or construed that the offer document has been cleared or approved by NSE nor does it certify the correctness or completeness of any of the contents of the Offer Document. The investors are advised to refer to page 226 of the Red Herring Prospectus for the full text of the Disclaimer clause of National Stock Exchange of India Limited.

GENERAL RISK: Investments in equity and equity-related securities involve a degree of risk and investors should not invest any funds in this issue unless they can afford to take the risk of losing their investment. Investors are advised to read the risk factors carefully before taking an investment decision in this Issue. For taking an investment decision, investors must rely on their own examination of the Issuer and this Issue, including the risks involved. The Equity Shares have not been recommended or approved by the Securities and Exchange Board of India ("SEBI"), nor does SEBI guarantee the accuracy or adequacy of the contents of this Red Herring Prospectus. Specific attention of the investors is invited to "Risk Factors" on page 26 of the Red Herring Prospectus.

BEELINE LINK Intime Remus
BEELINE CAPITAL ADVISORS PRIVATE LIMITED
LINK INTIME INDIA PRIVATE LIMITED
REMUS PHARMACEUTICALS LIMITED
SEBI Registration Number: INM000012917
SEBI Registration Number: INR000004058
Address: C-101, 1st Floor, 247 Park, Lal Bahadur Shastri Marg, Vikhroli (West), Mumbai, Maharashtra, India - 400 083.
Tel. Number: +91 810 811 4949
Fax: +91 22 4918 6195
Email Id: remuspharmaceuticals.ipo@linkintime.co.in
Investors Grievance Id: remuspharmaceuticals.ipo@linkintime.co.in
Website: www.linkintime.co.in
Contact Person: Mr. Nikhil Shah
CIN: U67190GJ2020PTC114322

AVAILABILITY OF RED HERRING PROSPECTUS: Investors are advised to refer to the Red Herring Prospectus and the Risk Factors contained therein before applying in the Issue. Full copy of the Red Herring Prospectus is available on the website of the SEBI at www.sebi.gov.in, website of the Company at www.remuspharma.com, the website of the BRLM to the Issue at www.beelineb.com, the website of NSE i.e. www.nseindia.com, respectively.

AVAILABILITY OF BID-CUM-APPLICATION FORMS: Bid-Cum-Application forms can be obtained from the Registered Office of the Company: Remus Pharmaceuticals Limited, Telephone: +079- 2999 9857; BRLM: Beeline Capital Advisors Private Limited, Telephone: 079 4918 5784 and the Syndicate Member: Sunflower Broking Private Limited Telephone: +91 8905344010 and at the selected locations of the Sub-Syndicate Members, Registered Brokers, RTAs and CDPs participating in the Issue. Bid-cum-application Forms will also be available on the websites of NSE and the designated branches of SCSBs, the list of which is available at websites of the stock exchanges and SEBI.

ESCRROW COLLECTION BANK/ REFUND BANK/ PUBLIC ISSUE ACCOUNT BANK/ SPONSOR BANK: ICICI Bank Limited. UPI: Retail Individual Bidders can also Bid through UPI Mechanism. All capitalized terms used herein and not specifically defined shall have the same meaning as ascribed to them in the Red Herring Prospectus.

On behalf of Board of Directors For, REMUS PHARMACEUTICALS LIMITED
Place: Ahmedabad Date: May 09, 2023
Mr. Swapnil Jatindbhai Shah Chairman and Whole Time Director
Disclaimer: Remus Pharmaceuticals Limited is proposing, subject to applicable statutory and regulatory requirements, receipt of requisite approvals, market conditions and other considerations, to make an initial public offer of its Equity Shares and has filed the RHP with the Registrar of Companies, Ahmedabad on May 06, 2023 and thereafter with SEBI and the Stock Exchanges. The RHP is available on the websites of SEBI at www.sebi.gov.in, website of the Company at www.remuspharma.com, the website of the BRLM to the Issue at www.beelineb.com, the website of NSE i.e. www.nseindia.com, respectively. Any potential investors should note that investment in equity shares involves a high degree of risk and for details relating to the same, please refer to the RHP including the section titled "Risk Factors" beginning on page 26 of Red Herring Prospectus. The Equity Shares have not been and will not be registered under the U.S. Securities Act of 1933, as amended (the "Securities Act") or any state securities laws in the United States, and unless so registered, and may not be issued or sold within the United States, except pursuant to an exemption from, or in a transaction not subject to, the registration requirements of the Securities Act and in accordance with any applicable U.S. state securities laws. The Equity Shares are being issued and sold outside the United States in "offshore transactions" in reliance on Regulation S under the Securities Act and the applicable laws of each jurisdiction where such issues and sales are made. There will be no public offering in the United States.

OFFER OPENING ADVERTISEMENT FOR THE BUYBACK OF EQUITY SHARES THROUGH TENDER OFFER UNDER THE SECURITIES AND EXCHANGE BOARD OF INDIA (BUYBACK OF SECURITIES) REGULATIONS, 2018, AS AMENDED, ("SEBI BUYBACK REGULATIONS") FOR THE ATTENTION OF EQUITY SHAREHOLDERS/ BENEFICIAL OWNERS OF THE EQUITY SHARES OF TEAMLEASE SERVICES LIMITED.



TEAMLEASE SERVICES LIMITED

CIN: L74140KA2000PLC118395
Registered Office: 315 Work Avenue Campus, Ascent Building, Koramangala Industrial Layout, Jyoti Nivas College Road, Koramangala, Bangalore - 560 096. Tel. No.: +91-80-6824 3000 | Fax. No.: +91-80-6824 3001
Company Secretary and Compliance Officer: Alaka Chanda
E-mail: corporateaffairs@teamlease.com; Website: group.teamlease.com

PUBLIC ANNOUNCEMENT FOR THE ATTENTION OF EQUITY SHAREHOLDERS/ BENEFICIAL OWNERS OF EQUITY SHARES OF TEAMLEASE SERVICES LIMITED IN CONNECTION WITH THE BUYBACK OF EQUITY SHARES THROUGH THE TENDER OFFER UNDER THE SEBI BUYBACK REGULATIONS OFFER FOR BUYBACK UPTO 3,27,869 (THREE LAKH TWENTY SEVEN THOUSAND EIGHT HUNDRED AND SIXTY NINE ONLY) FULLY PAID UP EQUITY SHARES OF FACE VALUE OF 10 (INDIAN RUPEES TEN ONLY) EACH, REPRESENTING 1.92% OF THE EQUITY SHARES IN THE EXISTING TOTAL PAID-UP EQUITY CAPITAL OF THE COMPANY FROM ALL ELIGIBLE SHAREHOLDERS (EQUITY SHAREHOLDERS AS ON THE RECORD DATE, BEING APRIL 03, 2023) ON A PROPORTIONATE BASIS, THROUGH THE 'TENDER OFFER' PROCESS, AT A PRICE OF 3,050/- (RUPEES THREE THOUSAND FIFTY ONLY) PER EQUITY SHARE, PAYABLE IN CASH, FOR AN AGGREGATE MAXIMUM AMOUNT NOT 1,00,00,00,450 (INDIAN RUPEES ONE HUNDRED CRORE AND FOUR FIFTY RUPEES ONLY) (THE "BUYBACK") EXCLUDING THE TRANSACTION COSTS.

This Offer Opening Advertisement is to be read together with(a) the public announcement dated March 17, 2023, published on March 20, 2023, in all editions of the English national daily newspaper, namely Financial Express, in all editions of the Hindi national daily newspaper, Jansatta and in Bangalor edition of Kannada daily newspaper, namely, HosaDigantha (Kannada being the regional language of Bangalore, Karnataka wherein the registered office of the Company is located), each with wide circulation and (b) the letter of offer dated May 01, 2023 in connection with the Buyback ("Letter of Offer").

In terms of Regulation 8(i) of the SEBI Buyback Regulations, the Draft Letter of Offer was submitted to SEBI on March 28, 2022. SEBI, vide its letter dated April 26, 2023 ("SEBI Final Observation Letter"), issued its comments on the Draft Letter of Offer in terms of Regulation 8(ii) of the SEBI Buyback Regulations. These comments have been suitably incorporated in the Letter of Offer.

The dispatch of the Letter of Offer to the Eligible Shareholders of the Company holding Equity Shares on the Record Date i.e. April 03, 2023 has been completed by May 04, 2023 through electronic mode to the shareholders whose e-mail ids are available with the Company and through Speed post/registered post at the address registered in India for all the remaining shareholders.

The Letter of Offer and the Tender Forms are available on the website of the Registrar of the Company, i.e. KFin Technologies Limited i.e. www.kfintech.com, Company, i.e. group.teamlease.com, Manager to the Buyback, i.e. Edelweiss Financial Services Limited i.e. www.edelweissfin.com, BSE Limited, i.e. www.bseindia.com and National Stock Exchange of India Limited i.e. www.nseindia.com In case of non-receipt of the Letter of Offer, the Eligible Shareholders, if they so desire, may download the Letter of Offer or the Tender Forms from the websites indicated above.

The schedule of activities for the Buyback is as follows:

Table with 3 columns: Sr. No., Activity, Schedule of Activities (Day, Date). Activities include Board Meeting, Declaration of results, Public Announcement, Record Date, Buyback Opening Date, Buyback Closing Date, etc.

Note: Where last dates are mentioned for certain activities, such activities may take place on or before the respective last dates. We request you to refer to the website of the Designated Stock Exchange for notice, if any, in this regard.

It may please be noted that the Buyback shall be implemented using the "Mechanism for acquisition of shares through Stock Exchange" notified by the SEBI Circulars and following the procedure prescribed in the Companies Act, 2013 read with the Companies (Share Capital and Debentures) Rules, 2014 and the SEBI Buyback Regulations and as may be determined by the Board and on such terms and conditions as may be permitted by law from time to time. In this regard, the Company shall request BSE being the designated stock exchange ("Designated Stock Exchange") to provide a separate window (the "Acquisition Window") to facilitate placing of sell orders by the Eligible Shareholders who wish to tender their Equity Shares in the Buyback. The details of the Acquisition Window will be as specified by BSE from time to time. During the Tendering Period all Eligible Shareholders may place orders in the Acquisition Window, through their respective stock brokers ("Seller Broker") during normal trading hours of the secondary market.

In the event the Seller Broker of any Eligible Shareholder is not registered with BSE as a trading member/ stockbroker/, then that Eligible Shareholder can approach any BSE registered stock broker and can register himself by using web based unique client code application ("UCI online") facility through that BSE registered stock broker (after submitting all details as may be required by such BSE registered stock broker in compliance with applicable law). In case the Eligible Shareholders are unable to register himself by using UCI online facility through any other BSE registered stock broker, then that Eligible Shareholder may approach the Company's Broker i.e., Nuvama Wealth Management Limited (formerly known as Edelweiss Securities Limited) to place their bids subject to completion of KYC requirements by the Company's Broker.

For details of the procedure for tender and settlement, please refer to the "Procedure for Tender Offer and Settlement" on page 47 of the Letter of Offer. The non-receipt of the Letter of Offer by, or accidental omission to dispatch the Letter of Offer to, any person who is eligible to receive the Offer, shall not invalidate the Offer to any person who is eligible to receive this Letter of Offer to participate in the Buyback. For the Eligible Shareholders holding Equity Shares in demat form, submission of Tender Form and TRS to the Company, Manager or the Registrar is not mandatory. In case of non-receipt of the Letter of Offer, Eligible Shareholders may participate in the offer by applying on the Tender Form downloaded from the Company's website group.teamlease.com, or Registrar's portal (direct web link of the RTA) at https://kosmic.kfintech.com/karisma/buybackoffer2.aspx or obtain a duplicate copy of the same by writing to the Registrar to the Buyback or by providing their application on plain paper in writing signed by such shareholder (in case jointly held then signed by all shareholders), stating name, address, number of shares held, Folio No, Client ID number, DP name, DP ID number, number of Equity Shares tendered and other relevant documents. Eligible Shareholder(s) have to ensure that their bid is entered in the Acquisition Window prior to the closure of the Offer. Please note that the Company shall accept Equity Shares from the Eligible Shareholders on the basis of their holding and Buyback Entitlement. Eligible Shareholder(s) who intend to participate in the Buyback using the "plain paper" option as mentioned in this paragraph are advised to confirm their Buyback Entitlement from the Registrar to the Buyback, before participating in the Buyback.

MANAGER TO THE BUYBACK: Edelweiss Financial Services Limited
REGISTRAR TO THE BUYBACK: KFIN TECHNOLOGIES LIMITED
EDELWEISS FINANCIAL SERVICES LIMITED
801 - 804, Wing A, Building No 3, Inspire BKC, G Block, Bandra Kurla Complex, Bandra East, Mumbai - 400051
Tel. No.: +91 22 4009 4400
Contact Person: Lokesh Shah
Email: teamlease@edelweissfin.com
Website: www.edelweissfin.com
SEBI Registration No.: INM000010650
CIN: L99999MH1995PLC094641

Capitalized terms used but not defined in this Offer Opening Advertisement shall have the meaning assigned to such terms in the Letter of Offer.

FOR AND ON BEHALF OF THE BOARD OF DIRECTORS OF TEAMLEASE SERVICES LIMITED.
Name: Ashok Kumar Nedurumalli Designation: Managing Director
Name: Rituparna Chakraborty Designation: Executive Director
Name: Alaka Chanda Designation: Company Secretary and Compliance Officer
Date : May 09, 2023 Place : Bangalore

IN THE COURT OF THE CIVIL JUDGE AND JMFC AT TIPTUR C.MIS.No.97/2022
PETITIONER: M.S.Manjunath S/o. late Shivnanjappa, Aged about 62 years, R/o Malledevarahalli Village, Kasaba Hobli, Tiptur Taluk.

ಸಾರ್ವಜನಿಕ ಪ್ರಕಟಣೆ
ಇವು ಕೃಷಿಯಾಜ್ಞೆ ಅನ್ವಯಿಸುವ ಪ್ರಕಾರವಾಗಿರುವುದರಿಂದ, ಈ ಪ್ರಕಾರವನ್ನು ಮುಂದುವರಿಸುವುದಕ್ಕೆ ಮುನ್ನ, ಈ ಪ್ರಕಾರವನ್ನು ಮುಂದುವರಿಸುವುದಕ್ಕೆ ಮುನ್ನ, ಈ ಪ್ರಕಾರವನ್ನು ಮುಂದುವರಿಸುವುದಕ್ಕೆ ಮುನ್ನ...

ಸರ್ಕಾರ ಸಂಸ್ಥೆಗಳ ಅಪರ/ಬಂಟಿ ನಿಬಂಧಕರು (ನಿ.441) ದಾವಾ ಪಂಚಾಯತಿ ನ್ಯಾಯಾಲಯ
ಕರ್ನಾಟಕ ರಾಜ್ಯ ಸರ್ಕಾರ ಪಟ್ಟಣ ಬ್ಯಾಂಕುಗಳ ಮಾಹಾಂವರಳಿ ನಿ., ಬೆಂಗಳೂರು ಇವರ ನ್ಯಾಯಾಲಯದಲ್ಲಿ
ವ್ಯಾಜ್ಯ ಸಂಖ್ಯೆ : ಬಿ.ಆರ್./ಡಿ.ಎಂ.ಬಿ.ಎಚ್/745/2021-2022

ಮತದಾನ: ಸಂವಿಧಾನದ ಹಕ್ಕು ಸದಳಕೆಯಾಗಲಿ
ಹಿರಿಯರು: ನಮ್ಮ ಭಾರತ ಸಂವಿಧಾನ ನೀಡಿರುವ ಮತದಾನದ ಹಕ್ಕನ್ನು ಬಳಸಿಕೊಳ್ಳುವುದರ ಪ್ರತಿಯೊಬ್ಬ ಪೌರರ ಅದ್ವೈಕತೆಯಾಗಿದ್ದು, ಇದೇ ಮೇ 10 ರಂದು ನಡೆಯುವ ವಿಧಾನಸಭಾ ಚುನಾವಣೆಯಲ್ಲಿ 18 ವರ್ಷ ಮೇಲ್ಪಟ್ಟ ಪ್ರತಿಯೊಬ್ಬ ಪೌರರೂ ತಪ್ಪದೇ ಮತದಾನ ಮಾಡುವ ಮೂಲಕ ತಮ್ಮ ಕ್ಷೇತ್ರದಲ್ಲಿ ಅರ್ಹ ಅಭ್ಯರ್ಥಿಯನ್ನು ಆಯ್ಕೆ ಮಾಡಬೇಕೆಂದು ಎಂಬುದಾಗಿ ಬಿಎಲ್ ಶಿಲ್ಪಾ ಹೇಳಿದರು.

CHANGE OF NAME
I, MANJU, wife of Sudheesh, Aged about 27 years, D/o. Stephen, Residing at No. 11, 2nd Floor, Block No. 16, KDSB Slum Qtrs, Sulikunta Colony, Muthanallur Cross, Sarjapura Road, Bangalore - 560 103, do hereby declare that I have changed my name from MURSHIDA .PN. to MANJU vide affidavit dated 08.07.2021 sworn to before S.I. Balaguru, Notary, Govt. of India, Bengaluru.

ಬಿಡುಗಡೆ ಗಮನಕ್ಕೆ
ಪ್ರತಿ ಕೆಲಸದ ಪ್ರಕಟಣೆಯನ್ನು ಮೂಲಕವಾಗಿ ಮಾಡುವುದಕ್ಕೆ ಮುನ್ನ, ಈ ಪ್ರಕಾರವನ್ನು ಮುಂದುವರಿಸುವುದಕ್ಕೆ ಮುನ್ನ, ಈ ಪ್ರಕಾರವನ್ನು ಮುಂದುವರಿಸುವುದಕ್ಕೆ ಮುನ್ನ...

ಸರ್ಕಾರ ಸಂಸ್ಥೆಗಳ ಅಪರ/ಬಂಟಿ ನಿಬಂಧಕರು (ನಿ.441) ದಾವಾ ಪಂಚಾಯತಿ ನ್ಯಾಯಾಲಯ
ಕರ್ನಾಟಕ ರಾಜ್ಯ ಸರ್ಕಾರ ಪಟ್ಟಣ ಬ್ಯಾಂಕುಗಳ ಮಾಹಾಂವರಳಿ ನಿ., ಬೆಂಗಳೂರು ಇವರ ಅಪರ/ಬಂಟಿ ನಿಬಂಧಕರು

SALE OF DAMAGED VEHICLE
Sealed Proposals are invited on as is where is basis for Accident damaged vehicle, available for inspection at Below Mentioned Place.
Damaged Vehicle Details:
KA-16-N-1745 Hyundai Verna FL 1.6 CRDI SX / 2015 Sep, Diesel Model Regn. On 23-12-2015, First Owner. (WITH & WITHOUT RC). The Subject Vehicle is Laying At M/s. Advaita Motors Pvt. Ltd., Belavadi, Mysore, Mobile number 9844158552/9686668528.

IN THE COURT OF THE ADDL. CIVIL JUDGE AND JMFC AT TIPTUR C.MIS. No. 94/2023
PETITIONER: Nagaraju, S/o Giriappa, Aged about 65 years, Residing at Honnavalli Village, Honnavalli Hobli, Tiptur Taluk, Tumkur District.

ಪ್ರಕಟಣೆ
ಇವು ಕೃಷಿಯಾಜ್ಞೆ ಅನ್ವಯಿಸುವ ಪ್ರಕಾರವಾಗಿರುವುದರಿಂದ, ಈ ಪ್ರಕಾರವನ್ನು ಮುಂದುವರಿಸುವುದಕ್ಕೆ ಮುನ್ನ, ಈ ಪ್ರಕಾರವನ್ನು ಮುಂದುವರಿಸುವುದಕ್ಕೆ ಮುನ್ನ, ಈ ಪ್ರಕಾರವನ್ನು ಮುಂದುವರಿಸುವುದಕ್ಕೆ ಮುನ್ನ...

IN THE COURT OF X ADDL. CITY CIVIL & SESSIONS JUDGE AT BANGALURU P & SC No 219 of 2023 (CCH-26)
1. Divya Nanaiah, D/o late P.M. Ponnappa & P. Lalitha Ponnappa, W/o K.M.Nanaiah, aged about 58 years, 2. P.P. Bopanna, Late. P.M. Ponnappa & P. Lalitha Ponnappa, aged about 55 years, Both are R/At No A-012, A Block, Classic Royale Garden Apartment, Hennur main road, Bangalore North, Bangalore-560043. ... PETITIONERS

PUBLIC NOTICE
This is to inform the General Public that, my Clients N SRINIVAS, N.MANJUNATH, SHANKAR N., UMA BAI.N. Children of LATE N.B.NANDARAM SINGH & LATE Smt. RAJA LAKSHMI BAI.M., Residing at NO. 14, 3RD MAIN, BET COLLEGE ROAD, DODDABANASWADI, BENGALURU-560043, Mobile Number : 7019933545 declare that, N.SRINIVAS and Late Smt. RAJA LAKSHMI BAI.M. are the absolute owner and in peaceful possession of the Schedule Property, acquired by virtue of ABSOLUTE SALE DEED vide document number: KR-1-04664-2016-17, in respect of the property situated at NO. 14, 3RD MAIN, BET COLLEGE ROAD, DODDABANASWADI, BENGALURU-560043.

Table with columns: SCHEDULE-A, SCHEDULE-B, SCHEDULE-C, SCHEDULE-D, SCHEDULE-E, SCHEDULE-F, SCHEDULE-G, SCHEDULE-H, SCHEDULE-I, SCHEDULE-J, SCHEDULE-K, SCHEDULE-L, SCHEDULE-M, SCHEDULE-N, SCHEDULE-O, SCHEDULE-P, SCHEDULE-Q, SCHEDULE-R, SCHEDULE-S, SCHEDULE-T, SCHEDULE-U, SCHEDULE-V, SCHEDULE-W, SCHEDULE-X, SCHEDULE-Y, SCHEDULE-Z

Table with columns: ಸಾರ್ವಜನಿಕ ಪ್ರಕಟಣೆ, (ಭಾರತದ ದಿವಾಳಿತನ ಮಂಡಳಿ ನಿಯಮಗಳು, 2017ರ (ಸ್ವಯಂಚ್ಛ, ಸಮಾವೇಶ ಪ್ರಕ್ರಿಯೆ)ನಿಯಮ 14) ನೋಟೀಸ್ ಎಂಬ ಕೆ.ಎಸ್. ಲಿಮಿಟೆಡ್ ಸಂಸ್ಥೆಯವರ ಸಮಾಜಿಕ ಸೇವೆಗಳನ್ನು ಒಪ್ಪಿಕೊಳ್ಳುವುದಕ್ಕೆ ಸಂಬಂಧಿಸಿದ ವಿವರಗಳು

ಶಿವರಾಜ್ ಸಂಸ್ಥೆಗಳ ಅಪರ/ಬಂಟಿ ನಿಬಂಧಕರು (ನಿ.441) ದಾವಾ ಪಂಚಾಯತಿ ನ್ಯಾಯಾಲಯ
ಕರ್ನಾಟಕ ರಾಜ್ಯ ಸರ್ಕಾರ ಪಟ್ಟಣ ಬ್ಯಾಂಕುಗಳ ಮಾಹಾಂವರಳಿ ನಿ., ಬೆಂಗಳೂರು ಇವರ ಅಪರ/ಬಂಟಿ ನಿಬಂಧಕರು

mLease India to Work
OFFER OPENING ADVERTISEMENT FOR THE BUYBACK OF EQUITY SHARES THROUGH TENDER OFFER UNDER THE SECURITIES AND EXCHANGE BOARD OF INDIA (BUYBACK OF SECURITIES) REGULATIONS, 2018, AS AMENDED, ("SEBI BUYBACK REGULATIONS") FOR THE ATTENTION OF EQUITY SHAREHOLDERS/ BENEFICIAL OWNERS OF THE EQUITY SHARES OF TEAMLEASE SERVICES LIMITED

Tea Putting
OFFER OPENING ADVERTISEMENT FOR THE BUYBACK OF EQUITY SHARES THROUGH TENDER OFFER UNDER THE SECURITIES AND EXCHANGE BOARD OF INDIA (BUYBACK OF SECURITIES) REGULATIONS, 2018, AS AMENDED, ("SEBI BUYBACK REGULATIONS") FOR THE ATTENTION OF EQUITY SHAREHOLDERS/ BENEFICIAL OWNERS OF THE EQUITY SHARES OF TEAMLEASE SERVICES LIMITED

Public Notice regarding the buyback of equity shares of Team Lease Services Limited. The notice details the terms and conditions of the buyback offer, including the number of shares to be bought back and the price to be paid for each share.

Table with columns: SCHEDULE-A, SCHEDULE-B, SCHEDULE-C, SCHEDULE-D, SCHEDULE-E, SCHEDULE-F, SCHEDULE-G, SCHEDULE-H, SCHEDULE-I, SCHEDULE-J, SCHEDULE-K, SCHEDULE-L, SCHEDULE-M, SCHEDULE-N, SCHEDULE-O, SCHEDULE-P, SCHEDULE-Q, SCHEDULE-R, SCHEDULE-S, SCHEDULE-T, SCHEDULE-U, SCHEDULE-V, SCHEDULE-W, SCHEDULE-X, SCHEDULE-Y, SCHEDULE-Z